Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
August 28, 2023 at 09:17 am EDT
Share
Honz Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 321.27 million compared to CNY 220.03 million a year ago. Revenue was CNY 333.02 million compared to CNY 229.13 million a year ago.
Net income was CNY 16.31 million compared to net loss of CNY 87.77 million a year ago. Basic earnings per share from continuing operations was CNY 0.0362 compared to basic loss per share from continuing operations of CNY 0.195 a year ago. Diluted earnings per share from continuing operations was CNY 0.0362 compared to diluted loss per share from continuing operations of CNY 0.195 a year ago.
HONZ PHARMACEUTICAL CO., LTD., formerly HAINAN HONZ PHARMACEUTICAL CO., LTD., is principally engaged in the research, development, production and distribution of drugs for children. The Company provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The Company's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.
HONZ PHARMACEUTICAL CO., LTD. 
